Cargando…

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab

OBJECTIVE: Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ran, Ran, Huang, Wenfa, Liu, Yaxin, Shao, Lin, Liu, Xiaoran, Niu, Yunyun, Kong, Weiyao, Bo, Shiping, Rugo, Hope S, Lu, Sijia, Li, Huiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245474/ https://www.ncbi.nlm.nih.gov/pubmed/32547071 http://dx.doi.org/10.2147/OTT.S240990

Ejemplares similares

Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2021)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
por: Minuti, G, et al.
Publicado: (2012)

ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab
por: Ellegård, Sander, et al.
Publicado: (2019)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
por: Pietrantonio, Filippo, et al.
Publicado: (2023)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
por: Chien, A. Jo, et al.
Publicado: (2012)

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
por: Wang, Mengting, et al.
Publicado: (2022)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer
por: Li, Huiping, et al.
Publicado: (2016)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
por: Kong, Xiangyi, et al.
Publicado: (2019)

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
por: Li, Huiping, et al.
Publicado: (2018)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
por: Tan, Ryan Shea Ying Cong, et al.
Publicado: (2022)

Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers
por: Niu, Dongfeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kevu8fhnnl3mfnrbstkn57918n